리듬 파머수티컬스 (RYTM) 주가 전망: 목표주가, 배당, 최신 뉴스

Rhythm Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.

It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency.

The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc.

was founded in 2008 and is headquartered in Boston, Massachusetts.

Rhythm Pharmaceuticals, Inc.는 상업화 단계의 바이오제약사로서 미국을 비롯한 해외에서 희귀 신경내분비 질환 치료제 개발에 주력하고 있습니다. 주요 제품은 IMCIVREE(setmelanotide)로, MC4R 계열의 작용제로서 pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) 결핍성 비만, Bardet‑Biedl 및 Alström 증후군, Prader‑Willi 증후군, 시상하부 비만 등의 적응증을 겨냥하고 있습니다.

IMCIVREE는 acquired hypothalamic obesity, congenital hypothalamic obesity, POMC 및 LEPR insufficiency 비만, SRC1 결핍 비만, SH2B1 결핍 비만에 대해 Phase 3 임상시험을 진행 중이며, Prader‑Willi 증후군 및 MC4R 결핍 치료를 위한 Phase 2 임상도 진행 중입니다.

동사는 또한 경구용 소분자 MC4R 작용제인 bivamelagon을 MC4R 경로 질환 치료를 위해 Phase 2에서 개발 중이고, 차세대 MC4R 펩타이드 작용제인 RM‑718을 시상하부 비만 치료를 목적으로 Phase 1에서 개발하고 있습니다. 회사는 2008년에 설립되었고 2015년 10월에 사명을 Rhythm Metabolic, Inc.에서 Rhythm Pharmaceuticals, Inc.로 변경했으며 본사는 매사추세츠주 보스턴에 위치해 있습니다.

• 주소: 222 Berkeley Street, 12th Floor, Boston, MA 02116, United States

• 전화번호: 857 264 4280

• 웹사이트: https://rhythmtx.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 414